Zosano Pharma Corporation (NASDAQ:ZSAN) has a beta value of 3.75 and has seen 1,162,314 shares traded in the last trading session. The company, currently valued at $99.44 Million, closed the last trade at $0.93 per share which meant it lost -$0.01 on the day or -1.23% during that session. The ZSAN stock price is -229.03% off its 52-week high price of $3.06 and 64.73% above the 52-week low of $0.328. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.49 Million shares traded. The 3-month trading volume is 10.42 Million shares.
The consensus among analysts is that Zosano Pharma Corporation (ZSAN) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.08.
Zosano Pharma Corporation (NASDAQ:ZSAN) trade information
Despite being -1.23% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Apr 27 when the ZSAN stock price touched $0.9933 or saw a rise of 6.2%. Year-to-date, Zosano Pharma Corporation shares have moved 76.76%, while the 5-day performance has seen it change 1.69%. Over the past 30 days, the shares of Zosano Pharma Corporation (NASDAQ:ZSAN) have changed -22.36%. Short interest in the company has seen 7.97 Million shares shorted with days to cover at 0.76.
Wall Street analysts have a consensus price target for the stock at $2.17, which means that the shares’ value could jump 133.33% from current levels. The projected low price target is $2 while the price target rests at a high of $2.5. In that case, then, we find that the current price level is +168.82% off the targeted high while a plunge would see the stock lose 115.05% from current levels.
Zosano Pharma Corporation (ZSAN) estimates and forecasts
Figures show that Zosano Pharma Corporation shares have outperformed across the wider relevant industry. The company’s shares have gained +155.96% over the past 6 months, with this year growth rate of 34.69%, compared to 8.1% for the industry. Other than that, the company has, however Increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 66.7% and 42.9% for the next quarter. Revenue growth from the last financial year stood is estimated to be +1498.2%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +60.3% over the past 5 years. Earnings growth for 2021 is a modest +78.6%.
Zosano Pharma Corporation (NASDAQ:ZSAN)’s Major holders
Insiders own 0.7% of the company shares, while shares held by institutions stand at 13.44% with a share float percentage of 13.53%. Investors are also buoyed by the number of investors in a company, with Zosano Pharma Corporation having a total of 37 institutions that hold shares in the company. The top two institutional holders are Vanguard Group Inc. (The) with over 3.54 Million shares worth more than $1.87 Million. As of December 30, 2020, Vanguard Group Inc. (The) held 3.33% of shares outstanding.
The other major institutional holder is Aisling Capital Management LP, with the holding of over 2.72 Million shares as of December 30, 2020. The firm’s total holdings are worth over $1.43 Million and represent 2.56% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of December 30, 2020, the former fund manager holds about 2.41% shares in the company for having 2566514 shares of worth $1.35 Million while later fund manager owns 718.82 Thousand shares of worth $378.89 Thousand as of December 30, 2020, which makes it owner of about 0.68% of company’s outstanding stock.